Recent preclinical advances in mRNA and DNA-based candidates against Andes and Hantaan strains have shown strong immunogenicity and protection in animal models, yet none have advanced beyond early Phase 1 or into large-scale efficacy trials as of September 2026. Standard vaccine development timelines, combined with limited commercial incentives for this rodent-borne pathogen and the need for multi-strain coverage, keep licensed approval unlikely before year-end. A cruise-ship outbreak earlier this year raised visibility but has not triggered the accelerated funding or regulatory pathways required to compress Phase 2–3 testing into the remaining months. Trader consensus at 94.5% reflects these scientific and logistical barriers while acknowledging that unexpected emergency authorization or major new investment could still alter the outcome.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · UpdatedHantavirus vaccine in 2026?
Hantavirus vaccine in 2026?
6% chance
$131,707 Vol.
$131,707 Vol.
Dec 31, 2026
6% chance
$131,707 Vol.
$131,707 Vol.
Dec 31, 2026
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.Recent preclinical advances in mRNA and DNA-based candidates against Andes and Hantaan strains have shown strong immunogenicity and protection in animal models, yet none have advanced beyond early Phase 1 or into large-scale efficacy trials as of September 2026. Standard vaccine development timelines, combined with limited commercial incentives for this rodent-borne pathogen and the need for multi-strain coverage, keep licensed approval unlikely before year-end. A cruise-ship outbreak earlier this year raised visibility but has not triggered the accelerated funding or regulatory pathways required to compress Phase 2–3 testing into the remaining months. Trader consensus at 94.5% reflects these scientific and logistical barriers while acknowledging that unexpected emergency authorization or major new investment could still alter the outcome.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Market Opened: May 4, 2026, 10:39 AM ET
Volume
$131,707End Date
Jan 1, 2027Market Opened
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.Recent preclinical advances in mRNA and DNA-based candidates against Andes and Hantaan strains have shown strong immunogenicity and protection in animal models, yet none have advanced beyond early Phase 1 or into large-scale efficacy trials as of September 2026. Standard vaccine development timelines, combined with limited commercial incentives for this rodent-borne pathogen and the need for multi-strain coverage, keep licensed approval unlikely before year-end. A cruise-ship outbreak earlier this year raised visibility but has not triggered the accelerated funding or regulatory pathways required to compress Phase 2–3 testing into the remaining months. Trader consensus at 94.5% reflects these scientific and logistical barriers while acknowledging that unexpected emergency authorization or major new investment could still alter the outcome.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Volume
$131,707End Date
Jan 1, 2027Market Opened
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...Recent preclinical advances in mRNA and DNA-based candidates against Andes and Hantaan strains have shown strong immunogenicity and protection in animal models, yet none have advanced beyond early Phase 1 or into large-scale efficacy trials as of September 2026. Standard vaccine development timelines, combined with limited commercial incentives for this rodent-borne pathogen and the need for multi-strain coverage, keep licensed approval unlikely before year-end. A cruise-ship outbreak earlier this year raised visibility but has not triggered the accelerated funding or regulatory pathways required to compress Phase 2–3 testing into the remaining months. Trader consensus at 94.5% reflects these scientific and logistical barriers while acknowledging that unexpected emergency authorization or major new investment could still alter the outcome.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated
Beware of external links.
Beware of external links.
Frequently Asked Questions